Neurogene Statistics

Total Valuation

Neurogene has a market cap or net worth of $301.02 million. The enterprise value is $175.15 million.

Market Cap	301.02M
Enterprise Value	175.15M

Important Dates

The last earnings date was Monday, November 18, 2024, after market close.

Earnings Date	Nov 18, 2024
Ex-Dividend Date	n/a

Share Statistics

Neurogene has 14.83 million shares outstanding. The number of shares has increased by 116.71% in one year.

Current Share Class	14.83M
Shares Outstanding	14.83M
Shares Change (YoY)	+116.71%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	12.02%
Owned by Institutions (%)	59.84%
Float	5.08M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	282.24
Forward PS	n/a
PB Ratio	1.92
P/TBV Ratio	2.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	189.35
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.09, with a Debt / Equity ratio of 0.10.

Current Ratio	9.09
Quick Ratio	8.84
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-5,825.08

Financial Efficiency

Return on equity (ROE) is -53.63% and return on invested capital (ROIC) is -43.84%.

Return on Equity (ROE)	-53.63%
Return on Assets (ROA)	-39.75%
Return on Capital (ROIC)	-43.84%
Revenue Per Employee	$10,165
Profits Per Employee	-$36,000
Employee Count	91
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +56.64% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+56.64%
50-Day Moving Average	44.97
200-Day Moving Average	38.77
Relative Strength Index (RSI)	32.31
Average Volume (20 Days)	600,421

Short Selling Information

The latest short interest is 914,186, so 6.17% of the outstanding shares have been sold short.

Short Interest	914,186
Short Previous Month	934,605
Short % of Shares Out	6.17%
Short % of Float	18.01%
Short Ratio (days to cover)	7.15

Income Statement

In the last 12 months, Neurogene had revenue of $925,000 and -$3.28 million in losses. Loss per share was -$0.26.

Revenue	925,000
Gross Profit	-56.73M
Operating Income	-75.73M
Pretax Income	-55.44M
Net Income	-3.28M
EBITDA	-72.45M
EBIT	-75.73M
Loss Per Share	-$0.26

Full Income Statement

Balance Sheet

The company has $138.99 million in cash and $13.12 million in debt, giving a net cash position of $125.87 million or $8.49 per share.

Cash & Cash Equivalents	138.99M
Total Debt	13.12M
Net Cash	125.87M
Net Cash Per Share	$8.49
Equity (Book Value)	137.41M
Book Value Per Share	10.56
Working Capital	127.85M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$70.08 million and capital expenditures -$820,000, giving a free cash flow of -$70.90 million.

Operating Cash Flow	-70.08M
Capital Expenditures	-820,000
Free Cash Flow	-70.90M
FCF Per Share	-$4.78

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-8,186.59%
Pretax Margin	-5,756.43%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neurogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-116.71%
Shareholder Yield	-116.71%
Earnings Yield	-1.09%
FCF Yield	-23.55%

Analyst Forecast

The average price target for Neurogene is $60.80, which is 199.51% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$60.80
Price Target Difference	199.51%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Neurogene has an Altman Z-Score of 7.52 and a Piotroski F-Score of 1.

Altman Z-Score	7.52
Piotroski F-Score	1